{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360298339727472000.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1089/mab.2021.0036"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/full-xml/10.1089/mab.2021.0036"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/pdf/10.1089/mab.2021.0036"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody (134-mG\n                    <sub>2a</sub>\n                    -f) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>\n                    The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein. Although EGFR is physiologically essential in normal cells, it contributes to tumor malignancy through gene amplification and/or protein overexpression, which augment signaling cascades in tumor cells. We previously developed an anti-human EGFR (hEGFR) monoclonal antibody (mAb), EMab-134 (mouse IgG\n                    <jats:sub>1</jats:sub>\n                    , kappa), which detects hEGFR and dog EGFR (dEGFR) with high sensitivity and specificity. The mouse IgG\n                    <jats:sub>2a</jats:sub>\n                    version of EMab-134 (134-mG\n                    <jats:sub>2a</jats:sub>\n                    ) has antitumor effects toward mouse xenografts of hEGFR-expressing oral squamous cell carcinomas. Furthermore, 134-mG\n                    <jats:sub>2a</jats:sub>\n                    -f, the defucosylated version of 134-mG\n                    <jats:sub>2a</jats:sub>\n                    , exhibits antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in dEGFR-overexpressed CHO-K1 (CHO/dEGFR) cells and antitumor activities in mouse xenografts of CHO/dEGFR cells. Herein, the reactivity of 134-mG\n                    <jats:sub>2a</jats:sub>\n                    -f against canine cancer cells with endogenous dEGFR was first examined by flow cytometry and immunocytochemistry.\n                    <jats:italic toggle=\"yes\">In vitro</jats:italic>\n                    analysis demonstrated that 134-mG\n                    <jats:sub>2a</jats:sub>\n                    -f highly exerted ADCC and CDC for a canine osteosarcoma cell line, D-17, which expresses endogenous dEGFR. Moreover,\n                    <jats:italic toggle=\"yes\">in vivo</jats:italic>\n                    administration of 134-mG\n                    <jats:sub>2a</jats:sub>\n                    -f significantly suppressed the development of D-17 compared with the results in response to control mouse IgG. These results suggest that 134-mG\n                    <jats:sub>2a</jats:sub>\n                    -f exerts antitumor effects against dEGFR-expressing canine cancers, and could be valuable as part of an antibody treatment regimen for them.\n                  </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380298339727472001","@type":"Researcher","foaf:name":[{"@value":"Ren Nanamiya"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472013","@type":"Researcher","foaf:name":[{"@value":"Junko Takei"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276175171072","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50442546"},{"@type":"NRID","@value":"1000050442546"},{"@type":"CINII_AUTHOR_ID","@value":"DA19602268"},{"@type":"URI","@value":"https://ci.nii.ac.jp/author/DA19602268#entity"},{"@type":"URI","@value":"https://viaf.org/viaf/NII%7CDA19602268"},{"@type":"NRID","@value":"9000400189063"},{"@type":"NRID","@value":"9000010419840"},{"@type":"NRID","@value":"9000383074269"},{"@type":"NRID","@value":"9000408482421"},{"@type":"NRID","@value":"9000343331435"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/tomokazu.ohishi"}],"foaf:name":[{"@value":"Tomokazu Ohishi"}],"jpcoar:affiliationName":[{"@value":"Microbial Chemistry Research Foundation, Institute of Microbial Chemistry (BIKAKEN), Numazu-shi, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472003","@type":"Researcher","foaf:name":[{"@value":"Teizo Asano"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472010","@type":"Researcher","foaf:name":[{"@value":"Tomohiro Tanaka"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1030285300704808960","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70837020"},{"@type":"NRID","@value":"1000070837020"},{"@type":"NRID","@value":"9000408480784"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/sano_masato"}],"foaf:name":[{"@value":"Masato Sano"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472000","@type":"Researcher","foaf:name":[{"@value":"Takuro Nakamura"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472004","@type":"Researcher","foaf:name":[{"@value":"Miyuki Yanaka"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472005","@type":"Researcher","foaf:name":[{"@value":"Saori Handa"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472009","@type":"Researcher","foaf:name":[{"@value":"Nami Tateyama"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472006","@type":"Researcher","foaf:name":[{"@value":"Yasuhiro Harigae"}],"jpcoar:affiliationName":[{"@value":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472008","@type":"Researcher","foaf:name":[{"@value":"Masaki Saito"}],"jpcoar:affiliationName":[{"@value":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472012","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Suzuki"}],"jpcoar:affiliationName":[{"@value":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472129","@type":"Researcher","foaf:name":[{"@value":"Manabu Kawada"}],"jpcoar:affiliationName":[{"@value":"Microbial Chemistry Research Foundation, Institute of Microbial Chemistry (BIKAKEN), Numazu-shi, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472128","@type":"Researcher","foaf:name":[{"@value":"Mika K. Kaneko"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1380298339727472007","@type":"Researcher","foaf:name":[{"@value":"Yukinari Kato"}],"jpcoar:affiliationName":[{"@value":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."},{"@value":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"21679436"},{"@type":"EISSN","@value":"21679436"}],"prism:publicationName":[{"@value":"Monoclonal Antibodies in Immunodiagnosis & Immunotherapy"}],"dc:publisher":[{"@value":"SAGE Publications"}],"prism:publicationDate":"2022-02","prism:volume":"41","prism:number":"1","prism:startingPage":"1","prism:endingPage":"7"},"reviewed":"false","dc:rights":["https://journals.sagepub.com/page/policies/text-and-data-mining-license"],"url":[{"@id":"https://journals.sagepub.com/doi/full-xml/10.1089/mab.2021.0036"},{"@id":"https://journals.sagepub.com/doi/pdf/10.1089/mab.2021.0036"}],"createdAt":"2022-02-28","modifiedAt":"2026-02-11","project":[{"@id":"https://cir.nii.ac.jp/crid/1040010457598535168","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"22K06783"},{"@type":"JGN","@value":"JP22K06783"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K06783/"}],"notation":[{"@language":"ja","@value":"大腸がん肝転移を規定する間質由来因子PAI-1を標的とした治療戦略の確立"},{"@language":"en","@value":"Establishment of a therapeutic strategy targeting the stromal-derived factor PAI-1 that regulates liver metastasis of colorectal cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1040850857191822208","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"21K07168"},{"@type":"JGN","@value":"JP21K07168"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K07168/"}],"notation":[{"@language":"ja","@value":"腫瘍型糖鎖構造を標的とした膜タンパク質に対する抗体医薬開発と腫瘍型糖鎖構造解析"},{"@language":"en","@value":"Development and characterization of cancer-specific monoclonal antibodies against tumor-associated glycoproteins."}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360013171524966784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparative proteome analysis of monolayer and spheroid culture of canine osteosarcoma cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013171867328000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013172362232064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013172487275008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The effect of Zhangfei/CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013172507374592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017279865059968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390759460736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021396136555648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antitumor Activity of an anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294645322189696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294648017693568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996–2006)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360301163937304448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302864795997824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865550196992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"EMab-300 Detects Mouse Epidermal Growth Factor Receptor-Expressing Cancer Cell Lines in Flow Cytometry"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865550796800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A Novel Anti-CD44 Variant 3 Monoclonal Antibody C44Mab-6 Was Established for Multiple Applications"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094294399232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094987692928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118759188480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 134-mG\n                    <sub>2a</sub>\n                    -f Exerts Antitumor Activities in Mouse Xenograft Models of Dog Epidermal Growth Factor Receptor-Overexpressed Cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576120076531712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Longevity and mortality in Kennel Club registered dog breeds in the UK in 2014"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576121731201152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of Carboplatin and Doxorubicin-Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576121997674112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576122621335040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576123021286912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidermal growth factor receptor in glioblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580230618181120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580230637139328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG2a-f) Exerts Antitumor Activity in Xenograft Model"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857597874343296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857597885955328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814743182208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A Rat Anti-Mouse CD39 Monoclonal Antibody for Flow Cytometry"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865816801741696","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Sensitive Anti-Mouse CD39 Monoclonal Antibody (C\n                    <sub>39</sub>\n                    Mab-1) for Flow Cytometry and Western Blot Analyses"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865816805154688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, C44Mab-34, for Multiple Applications against Oral Carcinomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521016871680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Methods and mortality results of a health survey of purebred dogs in the UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521116168192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Review of epidermal growth factor receptor biology"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996028729344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Use of Single-Agent Carboplatin as Adjuvant or Neoadjuvant Therapy in Conjunction With Amputation for Appendicular Osteosarcoma in Dogs"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470469752704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944639343104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893359890048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985–2004)"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368805552384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Myricetin treatment induces apoptosis in canine osteosarcoma cells by inducing DNA fragmentation, disrupting redox homeostasis, and mediating loss of mitochondrial membrane potential"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370140697856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Canine Osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370949846144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"What do we know about canine osteosarcoma treatment? – review"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794416366464","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270345850368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases"}]},{"@id":"https://cir.nii.ac.jp/crid/1370869448667927424","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update"}]},{"@id":"https://cir.nii.ac.jp/crid/1370869448667927425","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"AntiEGFR monoclonal antibody 134mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1089/mab.2021.0036"},{"@type":"KAKEN","@value":"PRODUCT-24257220"},{"@type":"KAKEN","@value":"PRODUCT-24037618"},{"@type":"OPENAIRE","@value":"doi_________::c752600a6f7cf4fc51f5771968f58d6f"},{"@type":"CROSSREF","@value":"10.1089/mab.2022.0022_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.3390/antib12020031_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.3892/ijmm.2023.5221_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.3390/antib12030042_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.3390/ijms24098411_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.1089/mab.2022.0023_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.3390/pharmaceutics14112494_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.3390/antib11040074_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.1089/mab.2023.0018_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.1089/mab.2023.0016_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"},{"@type":"CROSSREF","@value":"10.3390/biomedicines11041099_references_DOI_KtVzYg82qONQJR7HE5FKYA9nYXk"}]}